Analyst Research
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ligand Pharmaceuticals Inc Reaffirms FY 2012 Revenue Guidance
Ligand Pharmaceuticals Incorporated reaffirmed fiscal 2012 revenue guidance to be approximately $30 million.
Latest Developments for Ligand Pharmaceuticals Inc
- Ligand Pharmaceuticals Inc Reaffirms FY 2013 Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates
- Ligand Pharmaceuticals Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
- Ligand Pharmaceuticals Inc Announces Positive Preclinical Data On HepDirect Liver-Targeted Antiviral For Treatment Of Hepatitis
- Ligand Pharmaceuticals Inc Raises FY 2012 Revenue Guidance-Conference Call
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters